PTJ
PGNX

Paul Tudor Jones’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Paul Tudor Jones’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-31,817
Closed -$189K – 1357
2017
Q4 		$189K Buy
+31,817
New +$193K ﹤0.01% 970
2017
Q2 		– Sell
-10,100
Closed -$95K – 1511
2017
Q1 		$95K Buy
10,100
+5,900
+140% +$58.9K ﹤0.01% 1312
2016
Q4 		$36K Sell
4,200
-283,613
-99% -$2.1M ﹤0.01% 1342
2016
Q3 		$1.82M Sell
287,813
-2,054,575
-88% -$12.4M 0.04% 234
2016
Q2 		$9.88M Sell
2,342,388
-22,100
-0.9% -$107K 0.21% 57
2016
Q1 		$10.3M Sell
2,364,488
-6,272
-0.3% -$27.9K 0.26% 68
2015
Q4 		$14.5M Sell
2,370,760
-21,339
-0.9% -$140K 0.41% 44
2015
Q3 		$13.7M Buy
2,392,099
+4,391
+0.2% +$33.7K 0.46% 34
2015
Q2 		$17.8M Buy
2,387,708
+45,320
+2% +$274K 0.52% 38
2015
Q1 		$14M Sell
2,342,388
-28,115
-1% -$177K 0.45% 35
2014
Q4 		$17.9M Buy
2,370,503
+14,411
+0.6% +$86.2K 0.62% 12
2014
Q3 		$12.2M Buy
2,356,092
+13,704
+0.6% +$68.3K 0.44% 32
2014
Q2 		$10.1M Hold
2,342,388
– – 0.39% 49
2014
Q1 		$9.58M Sell
2,342,388
-407
-0% -$2.08K 0.41% 61
2013
Q4 		$12.5M Buy
2,342,795
+407
+0% +$1.79K 0.61% 31
2013
Q3 		$11.8M Hold
2,342,388
– – 0.48% 35
2013
Q2 		$10.4M Buy
+2,342,388
New +$10.5M 0.78% 31

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Paul Tudor Jones's PGNX Position: Q1 2018 in Review

Paul Tudor Jones sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2018, closing a stake of 31,817 shares — an estimated $189K sold.

Paul Tudor Jones first reported a position in PGNX in Q2 2013 and held it in 17 quarters. The position peaked at $17.9M in Q4 2014. 152 funds tracked by Wall St. Rank hold PGNX as of Q1 2018.

  • Paul Tudor Jones reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
  • Paul Tudor Jones sold 31,817 Progenics Pharmaceuticals Inc shares in Q1 2018, an estimated $189K.
  • Paul Tudor Jones first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 17 quarters.
  • Paul Tudor Jones's Progenics Pharmaceuticals Inc position peaked at $17.9M in Q4 2014.
  • 152 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2018.

Based on Tudor Investment Corp's 13F filing for Q1 2018, filed 15 May 2018.